$IONS Income Statement | Understand Stock

$IONS

$43.96 +$0.54 (1.24%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Product Sales, Net
Licensing and Other Royalties
Total product Sales, Net
R&D Revenue
Royalty Revenue
Other Commercial Revenue
Commercial Revenue
SPINRAZA Royalties
WAINUA Royalties
Total commercial Revenue
Collaborative Agreement Revenue
Eplontersen Joint Development Revenue
Total collaborative Agreement Revenue

WAINUA Joint Development Revenue
Research and Development Revenue
Total revenue

Expenses:
Cost of sales
Research, development and patent
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense):
Investment income
Interest expense
Interest expense related to sale of future royalties
Gain (loss) on investments, net
Loss on early retirement of debt
Gain (loss) on sale of real estate assets
Other income (expense), net
Loss before income tax benefit (expense)
Income tax benefit (expense)
Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.
Net loss
Basic net loss per share (in Dollars per share)
Diluted net loss per share (in Dollars per share)
Shares used in computing basic net loss per share (in Shares)
Shares used in computing diluted net loss per share (in Shares)

Comments